AP NEWS

Celiac Disease (CD) Report 2018 - Market Insights, Epidemiology and Market Forecast 2025 - ResearchAndMarkets.com

November 30, 2018

DUBLIN--(BUSINESS WIRE)--Nov 30, 2018--The “Celiac Disease (CD) - Market Insights, Epidemiology and Market Forecast 2025” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Celiac Disease (CD) - Market Insights, Epidemiology and Market Forecast 2025 provides an overview of the Celiac Disease, epidemiology for the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan and market trend of the Celiac Disease for the United States and EU5 (Germany, Spain, Italy, France and United Kingdom).

The report covers the therapeutics market revenue, treatment practice/algorithm and forecasted market size of Celiac Disease from 2015 to 2025 segmented by six major markets. In addition, The report also includes the forecasted epidemiology of Celiac Disease till 2025. The report also highlights the market drivers, market barriers and unmet medical need.

Our report provides the type specific prevalent, diagnosed and treatable population i.e. Gluten-free diet responsive CD and Refractory CD (along with RCD Type I and Type II). According to research, the prevalent population of Celiac Disease was estimated to be 4,027,782 in 2016. These are expected to grow for the study period i.e., 2015-2025. High prevalent cases were observed in United States as compared to EU5 and Celiac disease was found to be very rare in Japan with negligible prevalence.

There is no approved drug for the treatment of Celiac disease. Gluten free diet (GFD) is the only approach to diminish the symptoms of CD. Expected launch of Larazotide Acetate (Innovate Biopharmaceuticals), Latiglutenase (ImmunogenX), Vedolizumab (Takeda), NexVax (ImmusanT) and AMG-714 (CelImmune) in forecast period shall have a huge impact on the otherwise stagnant market size of Celiac Disease.

United States contributes the major share of CD market as compared to EU5 countries and Japan. The therapeutic market of CD in 7MM is expected to be USD 59.0 Million in 2016. This is expected to increase for the study period i.e., 2015-2025.

Key Coverage and Benefits:

The report will help in developing business strategies by understanding the trends shaping and driving the global Celiac Disease market. Organize sales and marketing efforts by identifying the best opportunities for Celiac Disease in US, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. The report provides historical as well as forecasted epidemiology of Celiac Disease in the 7MM covering United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan from 2015-2025. To understand the future market competition in the global Celiac Disease market and Insightful review of the key market drivers and barriers. To understand the regulatory scenario in major markets.

Key Topics Covered:

1. Report Introduction

2. Celiac Disease Market Overview at a Glance

3. Disease Background and Overview

3.1. Introduction

3.2. Types of Celiac Disease

3.3. Causes of Celiac Disease

3.4. Symptoms of Celiac Disease

3.5. Pathogenesis

3.6. Pathogenesis of RCD Type I:

3.7. Pathogenesis of RCD Type II:

3.8. Diagnosis

3.8.1. American college of Gastroenterology: Guidelines with Recommendations

3.8.2. British Society of Gastroenterology: Guidelines for the Diagnosis of Adult Coeliac Disease

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. Population and Forecast Parameters

5. United States

5.1. Prevalent Cases of Celiac Disease in the United States

5.2. Diagnosed cases of Celiac Disease in the United States

5.3. Treatable Cases of Celiac Disease in the United States

6. Germany

6.1. Prevalent Cases of Celiac Disease in Germany

6.2. Diagnosed cases of Celiac Disease in Germany

6.3. Treatable Cases of Celiac Disease in Germany

7. France

7.1. Prevalent Cases of Celiac Disease in France

7.2. Diagnosed cases of Celiac Disease in France

7.3. Treatable Cases of Celiac Disease in France

8. Spain

8.1. Prevalent Cases of Celiac Disease in Spain

8.2. Diagnosed cases of Celiac Disease in Spain

8.3. Treatable Cases of Celiac Disease in Spain

9. Italy

9.1. Prevalent Cases of Celiac Disease in Italy

9.2. Diagnosed cases of Celiac Disease in Italy

9.3. Treatable Cases of Celiac Disease in Italy

10. United Kingdom

10.1. Prevalent Cases of Celiac Disease in the United Kingdom

10.2. Diagnosed cases of Celiac Disease in the UK

10.3. Treatable Cases of Celiac Disease in the UK

11. Japan

11.1. Prevalent Cases of Celiac Disease in Japan

12. Treatment of Celiac Disease

12.1. Treatment of Non-Responsive or Refractory Celiac Disease (RCD)

12.2. Therapy areas in Celiac Disease

12.3. American College of Gastroenterology: Guidelines with Recommendations for the management of Celiac Disease

12.4. British Society of Gastroenterology: Guidelines for the Management of Adult Coeliac Disease

13. Unmet needs

14. Key drugs in Development

15. Key Cross Competition

16. Emerging Drugs Chapters

17. Larazotide Acetate: Innovate Biopharmaceuticals

18. Latiglutenase (ALV003): ImmunogenX

19. AMG 714: Celimmune

20. Nexvax2: Immusant Inc.

21. BL-7010: BioLineRx Ltd

22. Vedolizumab: Takeda Pharmaceuticals

23. Celiac Disease: Market Analysis

23.1. Key Findings

24. Global Market Size of Celiac Disease

Companies Mentioned

Takeda Pharmaceuticals BioLineRx Ltd Immusant Inc. Celimmune ImmunogenX Innovate Biopharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/n2z34h/celiac_disease?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181130005432/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Immune Disorders Drugs,Gastrointestinal Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 11/30/2018 01:22 PM/DISC: 11/30/2018 01:22 PM

http://www.businesswire.com/news/home/20181130005432/en

AP RADIO
Update hourly